Citius Pharmaceuticals : CTXR Presentation

Citius Pharmaceuticals, Inc.

(NASDAQ: CTXR)

Corporate Overview

JANUARY 2022

FORWARD-LOOKING STATEMENTS

This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the Company or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. The information contained in this presentation and the comments and remarks of the representatives of the Company made during any presentation to which this presentation relates are integrally related and, as such, are intended to be delivered and understood together. Information provided in this presentation speaks only as of the date hereof. The Company assumes no obligation to update any statement after the date of this presentation as a result of new information, subsequent events or any other circumstances.

This presentation also includes express and implied forward-looking statements regarding the current expectations, estimates, opinions and beliefs of the Company that are not historical facts. Such forward-looking statements may be identified by words such as "believes", "expects", "endeavors", "anticipates", "intends", "plans", "estimates", "projects", "should", "objective" and variations of such words and similar words. The accuracy of such statements is dependent upon future events, and involves known and unknown risks, uncertainties and other factors beyond the Company's control that may cause actual results to differ materially from what is presented herein. Investors are strongly encouraged to carefully review the Company's SEC filings for a listing of the risks that could cause actual results to differ from these forward looking statements. These forward-looking statements speak only as of the date of this presentation and should not be construed as statements of facts.

NASDAQ: CTXR	2

CITIUS: BUILDING A BIOTECH PLATFORM

Citius is a late-stagebiopharmaceutical company dedicated to the development and

commercialization of first-in-class critical care products

LMB merges with Citius Pharmaceuticals, Inc. (CTXR); up-listed to NASDAQ

CTXR raises	Multiple catalysts
$127.6M through	anticipated across
financing activities	platform

2013			2020		2021
	2016		2021		2022
Leonard Meron		CTXR in-licenses	CTXR acquires license
Biosciences, Inc. (LMB)	i-MSCs and forms	of Eisai's E7777
founded		NoveCite subsidiary	(I/ONTAK)
HALO-LIDO	MINO-LOK		MINO-WRAP		NC i-MSC	I/ONTAK
Rx therapy for	Salvage CVCs	Prevent infections		Treat ARDS	Treat CTCL,
hemorrhoids			associated with breast	with i-MSCs	PTCL, I/O
			Implants post-
			mastectomy
	2013				2020	2021

NASDAQ: CTXR	3

PHASE 3

INVESTMENT HIGHLIGHTS

DIVERSIFIED

PIPELINE WITH

MULTIPLE EXPECTED

CATALYSTS IN 2022

LARGE

ADDRESSABLE

MARKETS

• Five Active Programs

• I/ONTAK: purified reformulation of IL-2 diphtheria toxin fusion protein for CTCL

• Mino-Lok® : potential to be first and onlyFDA-approved product to salvage infected CVCs causing CRBSI/CLABSI

• • NC i-MSC™: novel stem cell therapy for acute respiratory distress syndrome (ARDS)
  • Halo-LidoRx: potential to be first and onlyFDA-approved Rx therapy for hemorrhoids
  • Mino-Wrap:potential to be first and onlyFDA-approved product to prevent infections associated with post mastectomy breast implants
• Multi-billion$ global market opportunities
• • CTCL market est. >$300M with larger potential in PTCL and immuno-oncology (I/O)
  • CRBSI/CLABSI market est. >$1.8B worldwide
  • ARDS market large with no approved therapies
  • Tissue expander infection prevention est. $400M worldwide
  • Rx hemorrhoid market est. >$2B US

SEASONED	• Extensive pharma operational and financial track record
MANAGEMENT &	• History of multi-billion $ in successfully completed transactions (pre-Citius)
ADVISORS	• Scientific Advisory Boards of leading KOL's in infectious disease, pulmonology
(ARDS), and breast surgery
STRONG FINANCIAL	• Cash runway into 2023 ($70.1M cash as of 9/30/21)
• $26.5M invested by management / founders
PLATFORM

NASDAQ: CTXR	4

DIVERSIFIED PIPELINE WITH FIVE ACTIVE PROGRAMS

PROGRAM	INVESTIGATIONAL	ESTIMATED	PRECLINICAL	PHASE I	PHASE II	PHASE III	ANTICIPATED
MARKET
INDICATION	MILESTONES
	(WW)

I/ONTAK	IL-2R CANCER	>$300M	BLA 2022
(E7777)	IMMUNOTHERAPY*
MINO-LOK®	TREAT CVC	> $1.8B	End Ph 3 2022
(CITI-001)	INFECTIONS
HALO-LIDO	RX THERAPY FOR	> $2B	Ph 2b 2022
(CITI-002)	HEMORRHOIDS
MINO-WRAP	PREVENT
INFECTIONS	> $400M	IND 2022
(CITI-101)	ASSOCIATED WITH
	BREAST IMPLANTS
NC i-MSC™	TREAT ARDS	Multi-billion	IND 2022
(CITI-401)
* Anti-IL-2 receptor
As of 1/2022, best estimate subject to impact of COVID-19 pandemic on operations

NASDAQ: CTXR	5